Emerging biosimilars market presents opportunities and challengesDecember 6, 2018Patient & Survivor Care
Immunotherapy may hold the key to defeating virally associated cancersNovember 25, 2018Head & Neck/Thyroid CancersGenitourinary CancerGynecologic CancerGastroenterologyImmunotherapyLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Meeting the potential of immunotherapy: new targets provide rational combinationsAugust 15, 2018GastroenterologyBreast CancerGenitourinary CancerHead & Neck/Thyroid CancersImmunotherapyLymphoma & Plasma Cell DisordersMelanoma
Immunotherapies shape the treatment landscape for hematologic malignanciesAugust 15, 2018Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationImmunotherapy
Tumor heterogeneity: a central foe in the war on cancerJune 21, 2018ImmunotherapyPatient & Survivor Care
Expanding treatment options for diverse neuroendocrine tumorsDecember 15, 2017GastroenterologyLung Cancer
Hallmark tumor metabolism becomes a validated therapeutic targetDecember 10, 2017Breast CancerGastroenterologyGenitourinary CancerLeukemia, Myelodysplasia, Transplantation
Liquid gold: blood-based biopsies make headwayApril 1, 2017Genitourinary CancerBreast CancerPatient & Survivor Care
Expanding treatment options and ongoing challenges for urologic cancersNovember 21, 2016Genitourinary Cancer
Evolving therapeutic strategies maintain clinical momentum in melanomaJune 29, 2016MelanomaImmunotherapy
Multiple myeloma: newly approved drugs forge paradigm shift toward chronic diseaseApril 27, 2016Lymphoma & Plasma Cell Disorders
